Catheter Precision Announces Accepted Publication in Leading European Medical Journal

Catheter Precision (NYSE American: VTAK) announced that a VIVO study has been accepted for publication in EP Europace on April 13, 2026.

Rhea-AI Summary

Catheter Precision (NYSE American: VTAK) announced that a VIVO study has been accepted for publication in EP Europace on April 13, 2026. The 31‑patient study mapped 48 VTs and found ECGi mapping with VIVO accurately predicted arrhythmogenic substrate for scar‑dependent VT and may improve procedural efficiency.

The study reported VIVO localization in NICM patients showed 100% specificity and 66.7% sensitivity for epicardial VTs versus a four‑step ECG algorithm (sensitivity 50%, specificity 0%). The company plans a larger multi‑center study later in 2026.

Positive

• Study accepted in EP Europace, a leading electrophysiology journal
• VIVO mapped 48 ventricular tachycardias across 31 patients
• NICM specificity 100% and sensitivity 66.7% for epicardial VT localization
• Company plans a larger multi‑center study later in 2026

Negative

• Small sample size: only 31 patients, limiting statistical power
• Sensitivity below 70% (66.7%) may miss some epicardial VT localizations

Argus Apr 13 session

+2.52% close to close 0.7x rel. volume Open Argus

Details

News Market Reaction – VTAK

On Apr 13, the day this news came out, VTAK closed 2.52% above the previous close.

Data tracked by StockTitan Argus for the Apr 13 session.

Key Figures

Patient count: 31 patients VTs mapped: 48 VTs VIVO specificity: 100% +3 more

Patient count

31 patients

VIVO scar-dependent VT study

VTs mapped

48 VTs

Mapped with VIVO and standard systems

VIVO specificity

100%

Epicardial VT localization in NICM patients

VIVO sensitivity

66.7%

Epicardial VT localization in NICM patients

Algorithm sensitivity

50%

Traditional four-step ECG-based algorithm

Algorithm specificity

0%

Traditional four-step ECG-based algorithm

Historical Context

5 past events · Latest: Mar 25

5 events

1. Mar 25

   Aviation platform update

   24h Move

   -4.2%

   Expanded Flyte Hops Vision Jet regional platform and fleet growth plans.

2. Mar 31

   Earnings and strategy

   24h Move

   -3.8%

   Reported 2025 results with strong revenue growth and outlined strategic expansion.

3. Apr 02

   Asset sale process

   24h Move

   -1.1%

   Hired advisor to market cardiac electrophysiology assets and focus on Flyte.

4. Apr 06

   LockeT clinical data

   24h Move

   +2.1%

   Peer‑reviewed LockeT study in 139 patients showing strong safety and efficacy profile.

5. Apr 08

   Conference attendance

   24h Move

   -1.7%

   Planned presence at EHRA conference to showcase data and support LockeT adoption.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ventricular tachycardia, electrocardiographic imaging, electrophysiology, electroanatomical mapping, +3 more

7 terms

ventricular tachycardia medical

"highlights the feasibility of VIVO for scar-related ventricular tachycardia (VT)"

A fast, abnormal heartbeat that starts in the heart’s lower chambers and can sharply reduce blood flow, potentially causing dizziness, fainting or, in severe cases, sudden collapse; picture an engine running so fast it loses power. For investors, ventricular tachycardia matters because demand for drugs, devices, diagnostic tests and emergency care tied to this condition affects clinical trial results, regulatory approvals, revenue prospects and legal or safety risks for healthcare companies.

electrocardiographic imaging medical

"Accuracy of a non-invasive electrocardiographic imaging system in scar-dependent"

A noninvasive medical technique that maps the heart’s electrical activity by combining signals from sensors placed on the body with imaging data to create a detailed picture of where and how electrical impulses travel across the heart. Think of it as using an external radar to locate electrical “hot spots” inside the chest; investors care because it can make diagnosis and treatment of heart rhythm problems faster, safer and more precise, creating demand for related devices, software and clinical services.

electrophysiology medical

"leading European electrophysiology journal"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

electroanatomical mapping medical

"mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems"

A medical technique that builds a detailed 3D picture of the heart’s shape and its electrical activity, used during procedures to find and treat abnormal heart rhythms. Think of it as a GPS for the heart that helps doctors target therapy more precisely, which matters to investors because better mapping can improve procedure success, shorten operating time, raise adoption of specialized equipment, and influence revenue, regulation and reimbursement trends in cardiac device and services markets.

epicardial medical

"compares VIVO’s predictability of epicardial VTs to a four step ECG based algorithm"

Epicardial describes the outer surface or layer of the heart and anything that involves working on or near that outer layer. It matters to investors because treatments, devices, or procedures that target the epicardial area can have different technical challenges, safety profiles and regulatory requirements than those done inside the heart chambers—think of fixing wiring on the outside of a machine versus working inside it—which affects development costs, approval risks and market potential.

non-ischemic cardiomyopathy medical

"In patients with Non-ischemic cardiomyopathy (NICM), the VIVO localization had"

Non-ischemic cardiomyopathy is a condition where the heart muscle becomes weak or changes shape for reasons other than reduced blood flow from blocked coronary arteries. Think of the heart as a pump whose walls are stretched or stiffened by infection, genetics, toxins, or other causes rather than a clogged pipe; that weakened pump raises risks of heart failure, hospital stays and long-term treatment. Investors track it because its prevalence and severity drive demand for drugs, devices, diagnostic tests and care services, and can influence clinical trial and regulatory activity in the cardiovascular sector.

specificity medical

"the VIVO localization had a 100% specificity and 66.7% sensitivity"

Specificity measures how well a diagnostic test or screening correctly identifies people who do not have a condition — the percentage of healthy cases the test labels as negative. Think of it as a smoke alarm that stays quiet when there’s no fire; high specificity means fewer false alarms. For investors, specificity affects regulatory approval, clinical adoption, follow-up costs, and the perceived reliability and market potential of medical products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Clinical Evidence Further Demonstrates Efficacy and Accuracy of VIVO for Ventricular Procedures

FORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”) today announced that the results of a recently concluded VIVO study have been accepted in EP Europace, the leading European electrophysiology journal.

The EP Europace journal provides an avenue of communication for top-quality European and international original, scientific work and reviews in the fields of arrhythmias, pacing and cellular electrophysiology. The journal offers readers a collection of contemporary, original, peer-reviewed papers, invited papers and editorial comments, together with book reviews and correspondence.

The accepted manuscript titled “Accuracy of a non-invasive electrocardiographic imaging system in scar-dependent ventricular tachycardia: Relationship to arrhythmogenic substrate and imaging defined scar” highlights the feasibility of VIVO for scar-related ventricular tachycardia (VT) was led by Professor Tarv Dhanjal, MBChB(hons) PhD FRCP FESC FEHRA, Professor of Cardiology (University of Warwick). This study included 31 patients and mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems to determine accuracy. The study concluded that ECGi mapping with VIVO can accurately predict the arrhythmogenic substrate for scar-dependent VT and incorporation of ECGi mapping to conventional VT ablation workflows may improve procedural efficiency.

Of additional importance, this study compares VIVO’s predictability of epicardial VTs to a four step ECG based algorithm. In patients with Non-ischemic cardiomyopathy (NICM), the VIVO localization had a 100% specificity and 66.7% sensitivity, while a traditional four-step ECG-based algorithm had a sensitivity and specificity of 50% and 0%, further demonstrating VIVO’s capabilities to improve procedural workflow.David Jenkins, CEO of Catheter Precision, says, “This study demonstrates that VIVO works in a wide range of patients, including those with scar related ventricular tachycardia and that it can improve procedural workflow and reduce procedure time even in very difficult procedures like epicardial VT. We are very pleased with the outcomes of this study and plan to start a larger, multi-center study later this year to prove out these results on a larger scale.”  

About VIVO™  
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

#   #   #

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Catheter Precision (VTAK) announce on April 13, 2026 about the VIVO study?

They announced acceptance of a VIVO study for publication in EP Europace, demonstrating feasibility and accuracy in scar‑dependent VT mapping. According to the company, the study included 31 patients and mapped 48 VTs showing potential workflow benefits.

How accurate was VIVO in localizing epicardial VTs in NICM patients in the VTAK study?

VIVO localization showed 100% specificity and 66.7% sensitivity for epicardial VTs in NICM patients. According to the company, this outperformed a four‑step ECG algorithm that had 50% sensitivity and 0% specificity.

How many patients and VTs were included in the Catheter Precision VIVO study (VTAK)?

The study enrolled 31 patients and mapped 48 ventricular tachycardias using VIVO and standard mapping systems. According to the company, comparisons assessed VIVO accuracy versus conventional electroanatomical mapping workflows.

What potential clinical benefit did Catheter Precision claim for VIVO in VT ablation procedures?

VIVO may improve procedural efficiency and reduce procedure time when incorporated into conventional VT ablation workflows. According to the company, the study concluded ECGi mapping with VIVO can accurately predict arrhythmogenic substrate for scar‑dependent VT.

Will Catheter Precision (VTAK) follow up the published VIVO study with further research?

Yes. The company plans to start a larger, multi‑center study later in 2026 to validate these results on a broader scale. According to the company, this aims to prove findings in a larger patient population.